CO2022011661A2 - Anticuerpos contra la integrina αvβ8 para su uso en el tratamiento de la enfermedad renal - Google Patents
Anticuerpos contra la integrina αvβ8 para su uso en el tratamiento de la enfermedad renalInfo
- Publication number
- CO2022011661A2 CO2022011661A2 CONC2022/0011661A CO2022011661A CO2022011661A2 CO 2022011661 A2 CO2022011661 A2 CO 2022011661A2 CO 2022011661 A CO2022011661 A CO 2022011661A CO 2022011661 A2 CO2022011661 A2 CO 2022011661A2
- Authority
- CO
- Colombia
- Prior art keywords
- kidney disease
- αvβ8 integrin
- αvβ8
- tissue
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan métodos y composiciones para tratar una enfermedad renal, tal como enfermedad renal crónica (CKD), en los que los métodos y composiciones comprenden anticuerpos o un fragmento de unión al antígeno de estos que se unen de manera específica y selectiva a la integrina αvβ8 humana, de la que se descubrió, como se describe, que presenta una expresión muy elevada en células y tejido renales y, en particular, tejido renal enfermo o fibrótico. Los anticuerpos contra la integrina αvβ8 divulgados se unen a la integrina αvβ8 humana en el riñón y bloquean la activación de TGF-β a partir de su forma latente en el tejido renal. Los anticuerpos contra αvβ8 en los métodos divulgados reducen, atenúan o anulan la fibrosis renal, que está asociada con la actividad de la integrina αvβ8 y TGF-β en el tejido renal. Los anticuerpos y métodos divulgados tratan de manera eficaz la enfermedad renal, en particular, la fibrosis asociada con la enfermedad renal, tal como CKD, en individuos que lo necesiten.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966258P | 2020-01-27 | 2020-01-27 | |
PCT/EP2021/051753 WO2021151889A1 (en) | 2020-01-27 | 2021-01-26 | ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022011661A2 true CO2022011661A2 (es) | 2022-08-30 |
Family
ID=74561850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0011661A CO2022011661A2 (es) | 2020-01-27 | 2022-08-18 | Anticuerpos contra la integrina αvβ8 para su uso en el tratamiento de la enfermedad renal |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230112035A1 (es) |
EP (1) | EP4096785A1 (es) |
JP (1) | JP2023511686A (es) |
KR (1) | KR20220132567A (es) |
CN (1) | CN115151305A (es) |
AR (1) | AR121193A1 (es) |
AU (1) | AU2021213403A1 (es) |
BR (1) | BR112022014633A2 (es) |
CA (1) | CA3167390A1 (es) |
CL (1) | CL2022001999A1 (es) |
CO (1) | CO2022011661A2 (es) |
CR (1) | CR20220392A (es) |
EC (1) | ECSP22066085A (es) |
IL (1) | IL294814A (es) |
MX (1) | MX2022009165A (es) |
TW (1) | TW202140554A (es) |
WO (1) | WO2021151889A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP4219560A3 (en) * | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
EP2744823B1 (en) | 2011-08-17 | 2017-08-02 | The Regents of the University of California | Antibodies that bind integrin alpha-v beta-8 |
JP2017522289A (ja) | 2014-06-17 | 2017-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善されたα−Vβ−8抗体 |
WO2018227018A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
-
2021
- 2021-01-13 TW TW110101209A patent/TW202140554A/zh unknown
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202140554A (zh) | 2021-11-01 |
CR20220392A (es) | 2022-09-07 |
ECSP22066085A (es) | 2022-09-30 |
CL2022001999A1 (es) | 2023-01-27 |
KR20220132567A (ko) | 2022-09-30 |
CN115151305A (zh) | 2022-10-04 |
IL294814A (en) | 2022-09-01 |
JP2023511686A (ja) | 2023-03-22 |
EP4096785A1 (en) | 2022-12-07 |
BR112022014633A2 (pt) | 2022-09-13 |
CA3167390A1 (en) | 2021-08-05 |
AU2021213403A1 (en) | 2022-09-15 |
AR121193A1 (es) | 2022-04-27 |
MX2022009165A (es) | 2022-08-16 |
WO2021151889A1 (en) | 2021-08-05 |
US20230112035A1 (en) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022011661A2 (es) | Anticuerpos contra la integrina αvβ8 para su uso en el tratamiento de la enfermedad renal | |
EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
PE20081635A1 (es) | Agentes para suprimir la reaccion de rechazo cronica | |
CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
EA200901211A1 (ru) | Антигены белка с5 и их применение | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
UY28287A1 (es) | Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
BR112013023724A2 (pt) | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento | |
ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
CL2022000194A1 (es) | Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
PE20151893A1 (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular | |
BR112017022323A2 (pt) | método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit. | |
GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
UY37967A (es) | Compuestos y métodos para la reducción de la expresión de snca | |
BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
BR112022004861A2 (pt) | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro | |
ECSP10010716A (es) | Combinaciones farmaceuticas. | |
BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
EA201491048A1 (ru) | Соединения двухцепочечных рнк к casp2 и их применение | |
BR112022006184A2 (pt) | Tratamento baseado em biomarcadores da glomeruloesclerose segmentar focal e doença renal diabética |